A
Agenus D
D
AGEN
5.96000
USD
0.46
(8.36%)
مغلق
حجم التداول
27,646
الربح لكل سهم
2
العائد الربحي
-
P/E
0
حجم السوق
163,404,426
الأخبار المقالات
العنوان: Agenus
القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).